Background/Objectives: Dihydromyricetin (DHM), a flavonoid with abundant natural sources, potent bioactivity, and high safety, holds promise for translational applications, particularly in mitigating skin aging. However, its role and underlying mechanisms in counteracting skin aging induced by advanced glycation end products (AGEs) remain unclear. Methods: Eight-week-old male Sprague-Dawley (SD) rats were subcutaneously injected with 500 mg/kg D-galactose and administered DHM via gavage for 11 weeks. Additionally, senescent human skin fibroblasts (HFF-1) induced by AGEs were used for further investigation. Results: DHM treatment significantly alleviated D-galactose-induced skin aging in rats, with the most pronounced effects observed in the moderate-dose group (100 mg/kg). Compared to the aging group, DHM enhanced skin elasticity and preserved collagen levels. Moreover, DHM promoted cell proliferation in the skin. Further studies on AGE-induced senescent fibroblasts revealed that DHM markedly reduced multiple senescence-associated markers and stimulated cell proliferation by approximately a 1.5-fold increase. Transcriptomic analysis indicated that DHM upregulated genes related to the cell cycle and DNA repair while suppressing AGE-RAGE signaling and its downstream pathways. Notably, DHM downregulated AGER, the gene encoding the receptor for AGEs (RAGE). Molecular docking analysis demonstrated that DHM shares a binding site with other known RAGE inhibitors. Surface plasmon resonance (SPR) analysis further confirmed the high binding affinity of DHM to RAGE (K_D = 28.7 μM), which was stronger and more stable than that of FPS-ZM1 (K_D = 40.7 μM). Conclusions: DHM may attenuate glycation-induced skin aging in rats by functioning as a RAGE inhibitor, thereby suppressing AGE-RAGE signaling, delaying cellular senescence, and promoting cell proliferation.

With the increasing frequency of ultraviolet (UV) exposure in daily life and the exploration of anti-photoaging strategies, natural plant-derived compounds with anti-skin-aging properties have garnered significant attention. This study aimed to evaluate the efficacy of zein-chitosan-based nanocarriers in enhancing the bioavailability of epigallocatechin gallate (EGCG) and to elucidate its mechanisms in ameliorating skin photoaging. Utilizing a Balb/c mouse model of photoaging, we monitored skin conditions, analyzed skin barrier function parameters, and observed changes in skin tissue structure and collagen fibers through hematoxylin–eosin (H&E) and Masson staining. Immunohistochemical staining was employed to assess COL1A1 levels in the skin, while enzyme-linked immunosorbent assay (ELISA) was used to measure antioxidant enzymes, inflammatory cytokines, matrix metalloproteinases (MMPs), and NF-kB levels. The effects of orally administered EGCG nanoparticles on UV-induced skin aging were investigated. UV exposure significantly increased skin roughness, impaired skin barrier function, thickened the epidermis, reduced collagen content, decreased antioxidant enzyme activity, and elevated levels of inflammatory cytokines, MMPs, and NF-kB in the model group compared to the normal control group. EGCG nanoparticles markedly ameliorated these photoaging manifestations, with some indicators showing superior improvement compared to free EGCG. These findings suggest that EGCG nanoparticles exhibit enhanced anti-photoaging effects over free EGCG, highlighting the potential of nanocarriers as a promising strategy to improve the bioavailability of EGCG.